That series included observations on seventeen patients treated consecutively with 400 mg. sulphinpyrazone (Anturan), when the average plasma uric acid (PUA) fell to 6 -0 mg. per cent., 400 mg. sulphinpyrazone plus 400 mg. allopurinol (average PUA 3-7 mg. per cent.), and 400 mg. allopurinol alone (average PUA 4 -2 mg. per cent.). It also showed in eight cases that if allopurinol was stopped after a year's treatment, the PUA level gradually rose. During treatment the average PUA was 4 mg. per cent., one month later 6.5mg. per cent., and 2 months later 7-5 mg. per cent. During the year's therapy there was minimal toxicity. A study of the effect of allopurinol on uric acid and oxypurine excretion was also included.
Of that original series of 38 The present series of 54 cases consists of 51 men and three women. They were all asked whether they knew of any gout in the family; 52 per cent. replied in the negative and 48 per cent. knew of a family history of the disease. Of those with a positive history, the average age at onset of symptoms was 37, while the age at onset of the remainder averaged 47 years. All three women gave a positive family history of gout.
Toxicity was minimal; two had very slight rashes, not requiring alteration of treatment, and two had slight headaches if the dosage of allopurinol exceeded 300 mg. per day-one of these had serious renal damage. Five patients had had renal colic or gravel before treatment, but this trouble had ceased with use of the xanthine oxidase inhibitor. Although there was an initial tendency for allopurinol, like the uricosuric drugs, to stir up gouty attacks, this has been no serious problem since all patients were given as a routine daily colchicine for the first 6 weeks of therapy. As a precaution they were also issued with a 2-day supply of phenylbutazone in case of an acute attack; they were told in that event to take 800 mg. per day, but not to change the rest of their treatment.
The length of time the 54 patients have been under treatment with allopurinol is shown in Fig. 1 . The shortest duration of allopurinol therapy was over a year and the longest over 51 years (mean 2 years 4 months). The dosage on which they have been stabilized is given in Fig. 2 . Satisfactory maintenance dosage varied from nil for the two in remission, 100 mg. (1), and 200 mg. (8), to two patients requiring 600 mg. per day and two needing the concomitant use of sulphinpyrazone. The majority, 29 cases, required 300 to 400 mg. to produce complete cessation of attacks and to reduce the urate level to a nornial range. continuLed to take for 3 years as fulminant goUt developed every tinie lie reduced the dose. He then took probenecid 2 g. day plus colchicine, and this made the attacks less acute, but his joints were becoming permanently swollen and by the age of 48 he was developing discharging tophi on the heels. The attacks became worse with worry or exercise.
The treatimient was then changed to anturan 600 mug. day comibined with colchicine, but this gave little benefit and the PL'A was still 8 mg. per cent. At this period soiiie tophi were removed surgically. Phenylbutazone 600 mg. day controlled the acute attacks better than indomethiacin 100 mg.. but in spite of this regimen lie was rapidly becomiuing crippled; lie Could only rise from his chair with help becauLse of pain in the knees and he Could not wear shoes or boots.
In Februiary, 1965, at the age of 51, he began to take allopirinol 400 mg./day plus anturan 600 nig./day and after a rirontil thie PLUA had dropped to 4 6 img. per cent.
Ii 2 Dosage onr which 54 p/atienits were stabiliZed. r) nil group.bmj.com on October 13, 2017 -Published by http://ard.bmj.com/ Downloaded from and he was able to wear shoes for the first time for a year. At the end of 8 months he was able to dance after a fashion. He is still on this regimen and has had no real attacks for over a year. The joints are less swollen and all the tophi healed and smaller. CASE 2 (One of the two patients that have been able to discontinue all medication). A man aged 72 had his first attack at the age of 61. The PUA was on two occasions 8-9 and 10-4 mg. per cent.; on allopurinol 400 mg./day and anturan 600 mg./day, it came down to 3 * 2 mg. per cent. and on allopurinol alone it remained at 3 * 4 mg. per cent. After 7 months this treatment was stopped and 2 years later the PUA was only 4-8 mg. per cent., the patient having had only one slight gouty attack in this period after a surgical operation.
CASE 3 (Renal disease with a calculus and gravel).
A man aged 62, who gave a family history of gout, had his first attack at the age of 30 years. The PUA had been as high as 16 mg. per cent., and he was hypertensive with a blood urea level of 42 mg. per cent. There was a small calculus in the right renal pelvis. On anturan 400 mg./day, the PUA dropped to 6-I mg. per cent. but he had repeated attacks of pain in the loins as well as haematuria and gravel. When allopurinol 400 mg./day was added, the PUA fell to 2-3 mg. per cent. The attacks of haematuria and renal pain ceased and have not recurred in the last 2 years.
CASE 4 (Early gout).
A youth aged 17 developed attacks of pain and swelling in various joints after slight trauma at games. The PUA was found to be 8 * 6 mg. per cent. and the blood urea level 20 mg. per cent. On a dosage of allopurinol 400 mg.jday, the PUA steadily settled to 6-5 and then to 2 * 8 mg. per cent. After 4 months he is playing rugger and doing crosscountry running.
Discussion
The use of allopurinol was treated at first withextreme caution in view of possible long-term effects of interference with enzyme reactions, but no such ill-effects have come to light after 5 years. After an initial period of up to 6 weeks, during which regular colchicine administration is advisable, the gout nearly always comes under good control. In a few very severe cases anturan should be used at the same time. Phenylbutazone can be used for an occasional acute attack. The dose which can be as high as 800 mg./day should be gradually decreased, but the majority of patients require a maintenance dose of 400 to 300 mg./day. Toxicity is minimal and there is no evidence of loss of effectiveness after 5 years of administration.
As the use of allopurinol may well be required for life the question arises when it should be started. Se han realizado observaciones en 54 casos de gota bajo tratamiento con alopurinol, por periodos de entre uno y cinco afnos y medio. En todos los casos, la gota pudo ser controlada por completo, y dos pacientes estuvieron en condiciones de cesar el tratamiento. El 70 por ciento fue estabilizado satisfactoriamente en una dosis diaria de 300 a 400 mg., o menos. Dos requirieron anturan con alopurinol para producir alivio completo. En cinco casos con sintomas previos de colico o cAlculos renales, estos sintomas cesaron. La toxicidad fue minima y en ningfin caso tuvo que suspenderse el alopurinol. No se observ6 tendencia a la reducci6n del efecto al cabo de tratamiento prolongado continuo.
